Infectious diseases are among the leading causes of death globally, disproportionally affecting developing countries. As a global leader of in vitro diagnostics, we understand the importance of solutions that focus on the most critical diseases that impact public health. Our infectious disease immunoassay solutions provide high sensitivity and uncompromised specificity while delivering precise results to inform decisions on patient care.
High quality, infectious disease immunoassay solutions
Our assays deliver the accuracy and speed critical to helping labs deliver reliable detection of infectious diseases.
87.6% of VITROS® assays are designated World Class or Excellent as defined by Six Sigma – the best in the industry.*
*Per competitive Six Sigma published data.
Our VITROS® HIV Combo Test delivers early detection of acute HIV-1 infection with seroconversion panels data.
Enhanced chemiluminescence detection delivers immunoassay sensitivity and precision with fewer unnecessary dilutions, repeats and redraws.
VITROS® Syphilis Assay now available in the United States
Syphilis is a serious infection that can be passed to a fetus during pregnancy, potentially causing lifelong health issues or death for the baby. In 2022, the Centers for Disease Control and Prevention (CDC) reported that more than 3,700 babies were born with congenital syphilis, which is over ten times the number reported in 2012. When performed as part of a CDC-approved syphilis testing algorithm, VITROS Syphilis may be able to detect syphilis infections early in the disease lifecycle, even when nontreponemal tests might not yet be reactive*.
*DC Laboratory Recommendations for Syphilis Testing, United States, 2024 | MMWR
Fast, early detection with HIV testing solutions
HIV screening and detection play a critical role in prevention. Our VITROS® HIV Combo Test delivers early detection of acute HIV-1 infection with class-leading fourth-generation tests. Seroconversion panels data reveals that the VITROS HIV Combo test outperforms other fourth-generation tests by identifying the virus earlier.
The VITROS HIV Combo test helps the laboratory incorporate critical ID diagnostics without impacting laboratory quality and efficiency. The test is enhanced by the proprietary technologies only available on VITROS systems.
Built-in intelligent technologies enhance efficiency and precision
Intellicheck technology with Smart Metering automatically checks for clots and bubbles and reports on diagnostic checks throughout the testing process, limiting manual intervention.
Our MicroSensor technology automates detection of HIT interferences without the need for manual inspection so you can efficiently drive quality results, lower costs and count on accurate results the first time.
Our proprietary, enhanced chemiluminescence detection technology provides exceptional immunoassay precision for wide dynamic ranges across a broad test menu and disease states.
VITROS® infectious disease testing assay menu
Related products
